Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about solriamfetol
Marketing authorisation indication
2.1 Solriamfetol (Sunosi, Jazz Pharmaceuticals) has a marketing authorisation 'to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy)'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.
Price
2.3 The list price for solriamfetol is £177.52 for a 75 mg 28‑day pack and £248.64 for a 150 mg 28‑day pack (BNF online accessed February 2021). Costs may vary in different settings because of negotiated procurement discounts.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation